Rilpivirine resistance may be barrier to long-acting injectable treatment in South Africa
Rapid adherence testing sheds light on viral suppression and resistance
Experimental islatravir implants protect monkeys against HIV-like virus
Tenofovir disoproxil-based pill regains its position as first choice for PrEP in the US
Huge increase in PrEP uptake when services offer choice and flexibility, African studies show
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
Failure of integrase inhibitor-based regimens may be due to a completely novel form of resistance
Weight loss after treatment switch more likely for those with higher body mass
White blood cell changes on islatravir do not lead to a higher risk of infections
